1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study

Humaıdan, Peter; Bredkjær, Helle Ejdrup; Westergaard, Lars; Andersen, Claus Yding

doi:10.1016/j.fertnstert.2008.12.042

Cited by 244 publications

(214 citation statements)

References 35 publications

Supporting

Mentioning

194

Contrasting

Unclassified

Order By: Relevance

“…16 Sonuç olarak; erken luteal fazda olması gereken endojen LH seviyelerini ve/veya reprodüktif sonuçları korumak için standart LFD'de modifikasyonlar yapma gereği oluşmuştur. 17 Bu konuda yapılan bir Cochrane meta-analizinde; hCG kullanılan taze otolog sikluslardaki canlı doğum oranları %31 iken GnRHa kullanılan sikluslarda %12'dir. Donör sikluslarda hCG ve GnRHa kullanılan gruplar, canlı doğum oranları açısından karşılaştırılmış ve anlamlı fark saptanmamıştır.…”

Section: 10unclassified

“…22 Humaidan ve ark., yaptıkları birkaç ça-lışmada hem normo-responder hem de high-responder hastalarda yapılan GnRHa tetikleme sonrası HCG kullanımının reprodüktif sonuçları normalize ettiğini bildirmişlerdir. 16,17,23 Humaidan ve ark. OHSS için düşük veya riske sahip 390 hastayı dâhil ettikleri randomize kontrollü çalışmada, GnRHa tetiklemeyi takiben luteal faz desteği için hCG uygulaması ve yalnız hCG ile tetikleme metotlarının sonuçlarını karşılaştırmış-lardır.…”

Section: 10unclassified

See 1 more Smart Citation

Current Approaches to the Use of GnRH Agonist Trigger for Final Oocyte Maturation: Review

Seven¹,

Hassa²

2017

Turkiye Klinikleri J Gynecol Obst

View full text Add to dashboard Cite

Section: 10unclassified

Current Approaches to the Use of GnRH Agonist Trigger for Final Oocyte Maturation: Review

Seven¹,

Hassa²

2017

Turkiye Klinikleri J Gynecol Obst

View full text Add to dashboard Cite

“…Кроме этого, у пациенток, которые не имеют высокого риска разви-тия СГЯ, P. Humaidan и соавт. [44] предлагали соче-тать применение прогестерона и эстрогенов с болюс-ным введением одной дозы ХГ (1500 МЕ в день пунк-ции яичников) или повторным введением неболь-ших доз ХГ (500 МЕ ХГ 3 раза на следующий день после пункции и на 4-й и 7-й дни после пункции). Согласно данным E. Papanikolaou и соавт.…”

Section: почему эндометрий в протоколах стимуляции яич-ников часто явunclassified

Current scientific and practical luteal phase support strategies

Kogan¹,

Gerkulov²

2016

Probl. reprod.

View full text Add to dashboard Cite

Актуальные научно-практические направления в стратегии гормональной терапии в посттрансферном периоде И.Ю. КОГАН, Д.А. ГЕРКУЛОВ ФГБНУ «НИИ акушерства, гинекологии и репродукции им. Д.О. Отта» (дир. -акад. РАН Э.К. Айламазян), Санкт-Петербург, Россия, 199034 Проблема, сопровождающая все циклы стимуляции суперовуляции, -недостаточность лютеиновой фазы. Поддержка лютеиновой фазы (прежде всего назначение прогестерона) широко используется для увеличения частоты наступления имплантации, клинической беременности и родов. Однако внедрение в практическую деятельность новых стратегий, связанных с обеспечением безопасности протокола, а также острые конкурентные взаимоотношения на рынке фармакологических услуг ставят сегодня несколько вопросов научной обоснованности выбора того или иного варианта гормональной поддержки в посттрансферном периоде. The luteal phases of all stimulated IVF cycles are abnormal. Luteal phase support (mainly progesterone administration) is a common practice in infertility treatment to improve the implantation rate, clinical pregnancy rate, and delivery rate. However, new practical strategies aimed to improve protocol safety and commercial conflicts of interests between pharmacological companies necessitate to take desicion about methods of luteal phase support.

show abstract

“…1) One bolus of 1500 IU hCG 35 h after the triggering bolus of GnRHa, i.e. one hour after oocyte retrieval [6,7], was demonstrated to rescue the luteal phase, resulting in a reproductive outcome comparable with that of HCG triggering, and with no increased risk of OHSS [8]. However, when applied to patients at high-risk to develop severe OHSS, 26 % developed severe early OHSS requiring ascites drainage and hospitalization [9].…”

Section: Introductionmentioning

confidence: 99%

Triggering final follicular maturation—hCG, GnRH-agonist or both, when and to whom?

Orvieto

2016

J Assist Reprod Genet

View full text Add to dashboard Cite

Controlled ovarian hyperstimulation (COH) which combines GnRH antagonist co-treatment and GnRH-agonist (GnRHa) trigger has become a common tool aiming to eliminate severe early OHSS and to support the concept of an OHSS-free clinic. However, due to the reported significantly reduced clinical, efforts have been made to improve reproductive outcome. One of the suggested optional strategies aiming to improve outcome was the addition of low-dose (1500 IU) HCG bolus, administered, concomitant, 35 h or 5 days after the triggering bolus of GnRHa. All these regimens were demonstrated to rescue the luteal phase, resulting in improved reproductive outcome in patients at risk to develop severe OHSS, compared to GnRHa trigger alone, however, with the questionable ability to eliminate severe OHSS. Moreover, following the observations demonstrating comparable or even better oocyte\embryos quality following GnRHa, compared to hCG trigger, and the different effects of LH and hCG on the downstream signaling of the LH receptor, GnRHa is now offered concomitant to the standard hCG trigger dose to improve oocyte/embryo yield and quality. GnRHa and hCG may be offered either concomitantly, 35-37 h prior to oocyte retrieval (dual trigger), or 40 h and 34 h prior to oocyte retrieval, respectively (double trigger).

show abstract

1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study

Cited by 244 publications

References 35 publications

Current Approaches to the Use of GnRH Agonist Trigger for Final Oocyte Maturation: Review

Current Approaches to the Use of GnRH Agonist Trigger for Final Oocyte Maturation: Review

Current scientific and practical luteal phase support strategies

Triggering final follicular maturation—hCG, GnRH-agonist or both, when and to whom?

Contact Info

Product

Resources

About